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751Abstracts
clothes you wear?” exhibited DIF by gender in both psoriasis
and AD samples, indicating that women were signiﬁcantly more
likely than men (at the same level of QoL) to afﬁrm the item.
Finally, the extensive DIF by disease observed indicates that it is
not valid to compare the scores of AD and psoriasis patients
using this measure.
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OBJECTIVES: To assess the consequences of dermatological dis-
eases on the quality of life of the patients. METHODS: Every
Belgian Dermatologist received a sample of 30 questionnaires
including the DLQI and the SF-12 that they distributed during
the “National Week of Dermatology” to the ﬁrst 30 patients
coming to the consulting room. The SF-12 is a generic measure
of health status, composed of two dimensions, a Physical one
(PCS-12) and a Mental one (MCS-12). The lower the score, the
more the quality of life is affected. The DLQI is a questionnaire
designed to measure and compare disability in different skin con-
ditions. The higher the score, the more the quality of life is
affected. RESULTS: The male/female ratio was 37%/63% and
the mean age was 46.76 years. Concerning the patients ‘state of
health, MCS-12 and PCS-12 were respectively 43.8 (SD = 11.3)
and 48.1 (SD = 9.4); with a signiﬁcant difference in the mental
dimension between Flemish (46.4, SD = 10.6) and Walloons
(40.7, SD = 11.3) (p = 0.0001). The quality of life score, assessed
by the DLQI, shows a quality of life’s impairment with a score
of 6.1 (SD = 5.9). CONCLUSIONS: Our population reﬂect a
QoL impairment comparable to the ranges obtained when ini-
tially validating the DLQI; i.e. for patients suffering psoriasis the
DLQI mean score was 8.9, it was 4.3 for patients suffering from
acne, and 6.7 for patients with viral warts. Concerning patients’
health status we observe for every patient, whatever his skin
disease was, an important impairment in the mental dimension
of the SF-12 compared to a standard population and a slight one
for the physical dimension (except for patients with acne who
are younger, mean age = 28 years old).
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OBJECTIVES: The Psoriasis Index of Quality of Life
(PSORIQoL) is a 25-item quality of life (QoL) scale speciﬁc to
psoriasis. It has been shown to have excellent scaling properties
and to be reproducible and valid. The aim of the present study
was to assess the responsiveness of the PSORIQoL and provide
data that will aid in the interpretation of scores on the measure.
METHODS: Data from a 13-week, placebo-controlled clinical
trial in psoriasis were analysed. PSORIQoL responsiveness was
assessed using Effect Size (ES), Standardised Response Mean
(SRM) and the Responsiveness Statistic (RS). The Standard Error
of Measurement (SEM), a distribution-based method of inter-
preting scores was also calculated. An anchor-based Minimal
Important Difference (MID; which provides an assessment of
clinical meaningfulness) was derived by measuring QoL change
accompanying changes in disease severity on a six-point Investi-
gator’s Global Assessment (IGA). The IGA ranges from zero
(clear) to ﬁve (very severe disease). RESULTS: A total of 69 pso-
riasis patients completed the PSORIQoL (51/ 74% male; mean
age 43.8 +/- 11.7; baseline mean PSORIQoL = 12.2 +/- 6.4; 13-
week PSORIQoL = 9.8 +/- 7.1). Effect Sizes ranged from 0.37
for the placebo arm to 0.67 for the most potent treatment arm.
Changes for the whole sample were signiﬁcant over time (p =
.007), with SRM = 0.40 and RS = 0.51. According to ES, changes
of 1.3, 3.2, and 5.1 represent small, moderate and large changes
in PSORIQoL scores respectively. One SEM = 1.91; 1.96 SEM
= 3.75. A move from Severe to Moderate and from Moderate to
Mild disease on the IGA requires a change of 1.8 and 2.7 points,
respectively in PSORIQoL scores. CONCLUSIONS: The
PSORIQoL was shown to be responsive to treatment effects. The
MID for the measure is between two and three points.
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OBJECTIVES: To evaluate the prevalence of “sensitive skin”
among a representative sample of the French population.
METHODS: We questioned a representative sample of the entire
French population aged 15 years and above. The SF-12 is a
generic measure of health status. The SF-12 is composed of two
dimensions, a Physical Component Summary (PCS-12) and a
Mental Component Summary (MCS-12). The results are stan-
dardised on the general US population [mean score of 50 (SD =
10)], so results can be meaningfully compared to an average and
compared one another. The lower the score, the more the quality
of life is affected. The SF-12 was intended for parents in order
to assess their own quality of life. RESULTS: Out of the French
population aged over 15 years, 51.9% felt that they had sensi-
tive or very sensitive skin. An evaluation of the quality of life,
using SF-12, revealed a change in the mental dimension of the
score for subjects of both sexes, “very sensitive or sensitive”
compared with “slightly or not sensitive”: Men: 45.61 versus
49.70 (p < 0.0001), Women: 44.68 versus 47.30 (p = 0.0024).
In addition, comparisons of the various degrees of sensitivity
revealed signiﬁcant differences for both men (very sensitive:
43.57, sensitive: 46.12, slightly: 48.43, not sensitive: 51.34) and
women (very sensitive: 42.21, sensitive: 45.54, slightly: 46.99,
not sensitive: 47.84), showing that the alteration in the mental
dimension was more severe when the skin was more sensitive.
CONCLUSIONS: As measured by SF-12, the mental dimension
of their quality of life was affected.
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OBJECTIVES: The ICARE programme’s objective is to asses
patients’ knowledge of the consequences of sun exposure. Its
speciﬁcity and relevance are based on the fact that patients will
be asked to ﬁll in the questionnaire after a sunburn. METHODS:
Every patient coming to an outpatient pharmacy in order to
obtain an advice or treatment following a sunburn was remitted
a questionnaire assessing the consequences of sun exposure. The
Dermatology Life Quality Index (DLQI) is a validated question-
naire to measure and compare disability in different skin condi-
tions. RESULTS: First results showed evidence of a QoL
